BioStar Capital, a strategic healthtech venture capital firm focused on cardiovascular disease, orthopaedics, and robotics, has closed its fifth fund at $130.3m, more than the combined amount raised by the firm’s three previous funds.
Led by founder Louis Cannon, a cardiovascular physician, and orthopaedic surgeon Alan Davis, BioStar Capital’s Fund V portfolio already includes several medical device companies, including: Amplitude Vascular Systems (AVS), developing a groundbreaking intravascular lithotripsy device for treating heavily calcified arteries; Medical Microinstruments (MMI), the developer of a robotic device that permits doctors to operate at microsurgical levels for precision reconstruction of small blood vessels, nerves and lymphatics; and REVA Medical, which has developed the MOTIV Bioresorbable Scaffold that is designed to treat below-the-knee peripheral artery disease.
BioStar expects to invest in eight to 10 additional companies over the next five years.
